Xilio Therapeutics, Inc. (XLO) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$9.08

From 52W high−24.42%

Volume22936.00

Market cap$60.08M

P/E (TTM)—

P/S (TTM)0.9x

Div yield—

Key dataSep 18, 2026

Open

$9.08

From 52W high

−24.42%

Volume

22936.00

Market cap

$60.08M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

3.4x

P/E (TTM)

—

RSI (14)

45.8

MomentumView details →

1D Return

+1.00%

YTD Return

−0.33%

SummaryUpdated Jun 1, 2026

Xilio Therapeutics, Inc. (NASDAQ:XLO) is a clinical-stage biotechnology company founded in 2016 and headquartered in Waltham, Massachusetts. The company went public in October 2021 and focuses on developing innovative immunotherapies designed to enhance the immune system's ability to fight cancer. Xilio specializes in creating tumor-selective treatments that aim to overcome the limitations of traditional cancer immunotherapies by concentrating therapeutic activity specifically within the tumor microenvironment while minimizing systemic side effects.

Ask drillr about Xilio Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

3.4x

EV/Sales

−1.1x

P/S (TTM)

0.9x

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

99.46%

Net Margin

−34.06%

EBITDA Margin

−31.97%

ROE (TTM)

−30.21%

ROA (TTM)

−14.15%

Asset Turnover

0.40x

GrowthView details →

Revenue YoY

+327.25%

EPS YoY

+88.30%

FCF YoY

—

Revenue CAGR 3Y

+589.88%

EPS CAGR 3Y

+72.54%

EBITDA YoY

+63.35%

MomentumView details →

1D Return

+1.00%

YTD Return

−0.33%

1Y Return

−18.22%

RSI (14)

45.8

vs 50D SMA

−1.10%

vs 200D SMA

+3.55%

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

4.25x

Quick Ratio

4.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.33

EPS Surprise

44.07%

Beats (12Q)

7/12

Next Q EPS Est

−$0.82

Avg Surprise (4Q)

26.40%

Rev Surprise

46.95%

Financials snapshotView financials →

Revenue (TTM)

64.09M

Net Income (TTM)

−21.83M

Op. CF (TTM)

−60.60M

Next earningsNov 5, 2026 →

Latest newsMore news →

Xilio Therapeutics received FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 candidate.39d ago

Xilio Therapeutics reported Q2 2026 collaboration and license revenue of $18.7 million, up from $8.1 million in Q2 2025, with a net loss of $6.4 million compared to a $15.8 million loss a year earlier.40d ago

Similar companies

eXoZymes, Inc.EXOZ MiNK Therapeutics, Inc.INKT Fortress Biotech, Inc.FBIOP Clene Inc.CLNN Heron Therapeutics, Inc.HRTX PDS Biotechnology CorporationPDSB Find similar companies →

Latest newsMore news →

Xilio Therapeutics received FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 candidate.39d ago Xilio Therapeutics reported Q2 2026 collaboration and license revenue of $18.7 million, up from $8.1 million in Q2 2025, with a net loss of $6.4 million compared to a $15.8 million loss a year earlier.40d ago